Fulltext

p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma

Moch, H. ; Sauter, G. ; Gasser, T. ; Buchholz, N. ; Bubendorf, L. ; Richter, J. ; Jiang, F. ; Dellas, A. ; Mihatsch, M.

In: Urological Research, 1997, vol. 25, p. S25-S30

Ajouter à la liste personnelle
    Titre
    • p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma
    Auteur
    • Moch, H.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    • Sauter, G.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    • Gasser, T.. Clinics of Urology, University of Basel, CH-4003, Basel, Switzerland
    • Buchholz, N.. Clinics of Urology, University of Basel, CH-4003, Basel, Switzerland
    • Bubendorf, L.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    • Richter, J.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    • Jiang, F.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    • Dellas, A.. Clinics of Gynecology, University of Basel, CH-4003, Basel, Switzerland
    • Mihatsch, M.. Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Urological Research, 1997, vol. 25, p. S25-S30. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:317847
    Summary
    The clinical course of renal cell carcinoma (RCC) is highly variable. Overexpression of the p53 protein has been suggested as a possible prognostic parameter in RCC. Overexpression of the mdm-2 oncogene product has been shown to interact with the p53 function. To investigate the immunohistochemical overexpression of mdm-2 protein in comparison with that of p53 protein in RCC, 50 nonpapillary pT3 RCCs were immunostained for p53 protein (DO-7) and mdm-2 (1172). Tumor growth fraction (Ki-67 labeling index; MIB-1) was determined by immunohistochemistry. p53 positivity was detected in 16% of tumors. mdm-2 overexpression was seen in 30% of RCCs. There was a significant association between p53 and mdm-2 immunostaining (P=0.0006), suggesting that mdm-2 protein may contribute to p53 protein stabilization in RCC. p53 overexpression was associated with a high Ki-67 LI (P=0.0002), suggesting that p53 overexpression is involved in growth control in RCC. Survival analysis showed that Ki-67 LI (P=0.04) and p53 overexpression were associated with poor prognosis (P=0.0021), whereas mdm-2 overexpression was not related to patient outcome (P=0.73). A Cox regression analysis revealed tumor stage (P<0.001) and p53 overexpression (P<0.05) to be independent prognostic parameters. It is concluded that p53 but not mdm-2 may be of practical relevance in predicting patient prognosis in RCC